Clinical Trials Logo

Filter by:
NCT ID: NCT02503644 Completed - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

FASST
Start date: October 29, 2015
Phase: Phase 2
Study type: Interventional

Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences. IVA337 has a novel mechanism of action and this study is designed to compare IVA337 at two dose levels with a placebo control treatment. Patients will be unaware of the treatment they are receiving and will be randomized to one of three treatment arms , either IVA337 400mg bid, IVA337 600mg bid or placebo bid. They will receive drug for 48 weeks and during that time assessments will be made to monitor both the efficacy and safety of the treatment.

NCT ID: NCT02503293 Completed - Clinical trials for Primary Immunodeficiency

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Start date: July 29, 2015
Phase: Phase 4
Study type: Interventional

A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using pump or rapid push.

NCT ID: NCT02503085 Completed - Clinical trials for Healthy Volunteer Study

Ibuprofen Suspension Bioequivalence Study

Start date: June 2, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the rate and extent of absorption of Ibuprofen suspension formulations.

NCT ID: NCT02502591 Completed - Clinical trials for Pelvic Organ Prolapse

Pudendal Nerve Block for Postoperative Posterior Repair Pain Relief

PPPR
Start date: August 2015
Phase: Phase 2
Study type: Interventional

Rectocoele or a posterior vaginal prolapse (bulge in the vagina) is a frequent gynaecological condition. It is repaired by repairing and reinforcing the support to the vaginal wall at the back. A small cut is made through the lining of the back wall of the vagina. The supports to the rectum are reinforced with stitches and the bulging part of the vaginal wall cut away. The wound in the vagina is then stitched up. Rectocoele repair is usually carried under a general anaesthetic with women reporting moderate to severe degrees of pain post operatively on sitting down. A Pudendal Nerve Block (PNB) is a common analgesic (pain killing) technique often used for women who need an instrumental delivery during childbirth. It is also widely used during a range of surgical procedures (operations) as a preventive analgesia to help reducing post -operative pain. The investigators would like to see if using this technique during routine rectocele repair will help with post - op pain.

NCT ID: NCT02501161 Completed - Clinical trials for Diabetes Mellitus, Type 2

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

DUAL™ VIII
Start date: January 31, 2016
Phase: Phase 3
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.

NCT ID: NCT02500550 Completed - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Start date: October 9, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related haploidentical donor. All patients are planned to receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or halted for safety reasons.

NCT ID: NCT02500537 Completed - Clinical trials for Non-emergent, Abdominal or Thoracic Procedures

A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology

Start date: May 2015
Phase: N/A
Study type: Interventional

A post-market study of the Endo GIA™ Reinforced Reload with Tri-Staple™ Technology.

NCT ID: NCT02500043 Completed - Clinical trials for Refractory Metastatic Gastric Cancer

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Start date: February 24, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.

NCT ID: NCT02499874 Completed - HIV Clinical Trials

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Start date: August 2015
Phase: Phase 1
Study type: Interventional

The purpose of the study is to measure the drug levels in your blood and to find out whether a reduced dose (400mg) of the anti-HIV medication Efavirenz is safe when taken during pregnancy. The study will recruit HIV infected women who take Efavirenz as part of their anti-hiv treatment and who are pregnant. Efavirenz has been shown to be safe in pregnancy and at the standard dose that everybody takes of 600mg once a day, it shows levels that are enough to treat HIV and give birth to a HIV negative baby. Efavirenz at a dose of 400mg once daily works against HIV too but this dose has not been given to HIV positive pregnant women. People with HIV may benefit from using a dose of efavirenz of 400mg instead of 600mg, as lower drug doses could have fewer side effects and be tolerated better. Dose reduction would also make the drug cheaper. This would allow more people to be treated and free up money for other important work in the fight against HIV such as education and prevention programs. However, it is not known whether 400mg of Efavirenz works as well as 600mg of Efavirenz during pregnancy and this is why the investigators are conducting this study, which aims to measure the amount of Efavirenz 400mg in HIV pregnant women's bodies when they are taking 400mg of Efavirenz once a day.

NCT ID: NCT02499848 Completed - Prostate Cancer Clinical Trials

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Start date: July 2015
Phase: Phase 2
Study type: Interventional

To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.